Technology platform deal with Lanthio marks new approach for MorphoSys
This article was originally published in Scrip
Executive Summary
German firm, MorphoSys has outlined something of a shift in its strategy by signing a technology alliance deal with privately held, Dutch peptide drug company, Lanthio Pharma, to jointly develop the latter's drug discovery platform technology, LanthioPep.